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We have previously shown the safety and feasibility of vagus nerve stimulation (VnS) paired with 
upper-limb rehabilitation after ischemic stroke. in this exploratory study, we assessed whether clinical 
and brain MRi variables predict response to treatment. We used data from two completed randomised 
and blinded clinical trials (n = 35). All participants had moderate to severe upper-limb weakness and 
were randomised to 6-weeks intensive physiotherapy with or without VNS. Participants had 3 T brain 
MRi at baseline. the primary outcome was change in fugl-Meyer Assessment, upper-extremity score 
(FMA-UE) from baseline to the first day after therapy completion. We used general linear regression 
to identify clinical and brain MRi predictors of change in fMA-Ue. VnS-treated participants had 
greater improvement in FMA-UE at day-1 post therapy than controls (8.63 ± 5.02 versus 3.79 ± 5.04 
points, t = 2.83, Cohen’s d = 0.96, P = 0.008). Higher cerebrospinal fluid volume was associated with 
less improvement in fMA-Ue in the control but not VnS group. this was also true for white matter 
hyperintensity volume but not after removal of an outlying participant from the control group. 
Responders in the VnS group had more severe arm impairment at baseline than responders to control. A 
phase iii trial is now underway to formally determine whether VnS improves outcomes and will explore 
whether these differ in people with more severe baseline upper-limb disability and cerebrovascular 
disease.
Vagus nerve stimulation (VNS) paired with upper-limb rehabilitation is a potential novel treatment for arm 
weakness after stroke. VNS triggers release of plasticity promoting neuromodulators, such as acetylcholine and 
norepinephrine, throughout the cortex1. Timing this with motor training drives task-specific plasticity in the 
motor cortex2 and VNS paired with rehabilitative training has been shown to improve recovery in different pre-
clinical models of stroke, both in comparison to VNS alone and rehabilitation alone3,4. These improvements were 
associated with synaptic reorganization of cortical motor networks and recruitment of residual motor neurons 
controlling the impaired forelimb5. Two clinical studies comparing VNS paired with upper-limb rehabilitation 
with upper-limb rehabilitation alone have shown it to be acceptably safe and feasible and that it may improve arm 
weakness after ischemic stroke6,7.
Arm weakness is the most common symptom of stroke and approximately half of stroke survivors with arm 
weakness have prolonged disability, which is associated with reduced quality of life8,9. Restoration of arm function 
after stroke is a priority for many stroke survivors10. However, recovery of motor function after stroke varies, so 
identifying factors that help predict response is important to aid patient selection and identify those most likely to 
respond. This is particularly true where therapies are invasive (involving surgery) and/or time consuming; VNS 
requires implantation of a nerve stimulator which is costly and associated with risks of anaesthesia, a small risk 
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of infection and small risk of vocal cord palsy. There are several clinical and brain imaging markers that predict 
cognitive and functional recovery after stroke including age, level of impairment, white matter hyperintensity 
(WMH) volume, stroke lesion volume, corticospinal tract damage and blood pressure level11–13.
In the present study, we combined clinical and brain magnetic resonance imaging (MRI) data from our two 
previous randomised trials of VNS paired with rehabilitation for the upper-limb after ischemic stroke6,7. We per-
formed exploratory analyses to assess predictors of response to VNS paired with upper-limb rehabilitation. Our 
goal was to identify predictive factors for further study that may help with patient selection for this promising 
novel therapy.
Methods
Study design, participants, and therapy. We have previously performed two randomised, blinded 
clinical trials of VNS therapy paired with rehabilitation for upper-limb recovery after stroke (NCT01669161 
and NCT02243020)6,7. Data from these two trials were combined in the present analysis. The first trial was a 
Prospective Randomized Open, Blinded End-point (PROBE) study. The second was fully-blinded with sham 
stimulation. Approval was granted by the Medicine and Healthcare Regulatory Authority and by the West of 
Scotland Research Ethics Committee. All procedures performed in human participants were in accordance with 
the ethical standards of institutional committees and with the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards. Informed consent was obtained from all individual participants included in the 
study.
The trials have been described in detail elsewhere6,7. The first trial was a PROBE design with an active 
rehabilitation control and the second was a fully blinded study with sham stimulation where all participants 
were implanted with a VNS device. In both studies, the VNS device implantation was performed under gen-
eral anaesthesia by a surgeon. The device (Vivistim® System, MicroTransponder Inc., Austin, TX) consisted of 
an implantable pulse generator (IPG, Model 1001, MicroTransponder Inc., Austin, TX), an implantable lead 
(2.0 mm or 3.0 mm, Model 3000, MicroTransponder Inc., Austin, TX), and a wireless transmitter (Model 2000, 
MicroTransponder Inc., Austin, TX).
Participants had moderate to severe upper-limb weakness defined as a score of 20–50 on the Fugl-Myer 
Assessment, upper-extremity (FMA-UE) in both trials. The FMA-UE score assesses movement quality and syn-
ergy and is a well validated assessment of impairment. It ranges from 0 to 66 points. An improvement of greater 
than 6 points is typically defined as a clinically significant change being associated with improvement in function 
and quality of life14. Other inclusion and exclusion criteria were similar across trials and were fully described 
previously6,7.
The therapy protocol for both active VNS and control groups included 6-weeks of intensive upper-limb reha-
bilitation. Participants did in-clinic rehabilitation three times a week for 6 weeks, for a total of 18 sessions. All 
sessions started with 10 to 15 minutes of stretching exercises, followed by seven standardized tasks. Each session 
lasted approximately 2 hours. Functional tasks included reach and grasp, opening doors and locks, gross move-
ment, object flipping, simulated eating tasks, inserting objects, and opening containers. These standardized tasks 
were performed in this order during each therapy session. Participants did approximately 30–50 repetitions per 
task and spent 10–20 minutes doing each task. For each participant, tasks were graded in difficulty and adapted 
to each person’s abilities and goals. Therefore, the exact number of repetitions per task varied depending on the 
level of impairment.
The VNS group received active VNS combined with rehabilitation exercises, while the control group did the 
rehabilitation exercises without VNS pairing. The VNS stimulation settings in the active VNS group were 0.5 s 
of VNS (0.8 mA, constant current, charge balanced pulses, 100 µs pulse width, 30 Hz frequency) during each 
repetition of a therapy task in both trials. VNS was delivered by a push button, held in the therapist’s hand and 
connected wirelessly via a laptop to the VNS device, during each repetition in a therapy session. The mean num-
ber of stimulations per session were 444 for the VNS group and 511 for the control group. The control group had 
an outlier for number of stimulations per session and without their data the control group was similar to the VNS 
group at 464 stimulations per session. The mean number of stimulations per minute during each task was 4.9 and 
5.6 for VNS and control groups, respectively.
In the first PROBE design study, the therapist used the push button in the control group during therapy ses-
sions, but this was not connected to a VNS device as there was no sham implantation. In the second fully blinded 
study the push button connected wirelessly to the implanted VNS device in control participants but a 0.0 mA 
sham stimulation was delivered during each task.
Participants had baseline FMA-UE scores recorded and FMA-UE score was reassessed at the end of the 6 
weeks in clinic therapy. After this 6-week visit, the therapy protocol differed between the two trials, but these data 
are not included in this combined analysis.
Brain MRi acquisition and analysis. All participants had a structural brain MRI scan performed before 
randomisation unless contraindicated; the MRI protocol has been described in detail previously15. In brief, T1, 
T2, fluid attenuated inversion recovery (FLAIR), susceptibility-weighted (SWI), and diffusion tensor images 
were acquired using 3 T MRI. Stroke infarct volumes were manually segmented by an experienced image analyst 
(DAD) trained in accordance with STRIVE guidelines16. Segmentation of WMH and normal appearing tissue 
volumes was described previously15.
The corticospinal tract in each subject was estimated by diffeomorphically registering17 the “JHU DTI-based 
white-matter atlas”18 to each subject. Estimates of corticospinal tracts in each subject were visually inspected 
and approved. Whole brain mean diffusivity (MD) and fractional anisotropy (FA) maps were calculated using 
FMRIB’s Diffusion Toolbox19 and corticospinal tract masks were applied to the whole brain maps to calculate 
MD and FA within the corticospinal tract. Damage to the corticospinal tract was assessed using diffusion metrics 
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(MD and FA) in the corticospinal tract on the side of stroke divided by diffusion metrics on the unaffected side 
(known as “MD and FA ratios”)13.
Statistical analyses. The primary outcome measure was change in FMA-UE score between baseline and 
day-1 post therapy visit. All statistical analyses were performed using the Statistical Analysis System (SAS) version 
9.4 (© 2002–2012 SAS Institute Inc.). We used the “PROC TTEST” function to assess differences in continuous 
baseline variables and FMA-UE change scores between treatment groups. We used Fisher’s exact test to assess 
differences in proportional variables, e.g., sex, hemisphere of stroke, between groups.
We used the “PROC GENMOD” function in SAS to perform general linear regression with standardized 
beta to identify predictors of post-treatment FMA-UE score i.e., a regression-based change analysis. Prediction 
variables of post-treatment FMA-UE score were: time since stroke, cortical versus subcortical stroke, months of 
rehabilitation pre-randomisation, WMH volume, cortical grey matter volume, cerebral normal appearing white 
matter volume, supratentorial cerebrospinal fluid (CSF) volume, MD and FA in the corticospinal tract on the side 
of stroke versus non-affected side (referred to as MD and FA ratios henceforth)13, stroke infarct volume, systolic 
and diastolic blood pressure. We performed separate models for each predictor because there was a high risk of 
unstable beta coefficients with many predictors versus relatively limited sample sizes, i.e., by including all pre-
dictors in a single model there would have been a large number of variables relative to sample size; this can lead 
to unreliable results via lower degrees of freedom. We adjusted all analyses by baseline FMA-UE score, sex, and 
age, and performed each analysis separately in the control and VNS treated groups. We did not perform multiple 
comparisons testing due to the exploratory nature of this study.
Finally, we defined “responders” as those who had greater than or equal to a 6-point improvement in FMA-UE 
score. Previous studies assessing FMA-UE using anchor-based methods estimated that the clinically important 
difference ranged from 4.24 to 7.25 points and a >50% improvement (excellent improvement) in overall arm 
and hand function has been shown to correspond to a FMA-UE change of 5.25 points14. We used t-tests to assess 
baseline FMA-UE scores and imaging characteristics in control responders versus VNS responders to assess 





VNS + Rehabilitation 
(N = 16) Cohen’s d P-valuea
Age 59.6 ± 11.6 57.6 ± 12.5 0.1696 P = 0.6206
Male sex N = 13 N = 10 N/A P = 0.7362
Years since stroke 1.7 ± 1.2 1.6 ± 0.8 0.0721 P = 0.8331
Right dominant hand N = 16 N = 15 N/A P = 1.0000
Months of prior rehabilitation 20.5 ± 16.0 11.6 ± 13.5 0.5918 P = 0.1391
Right paretic limb N = 9 N = 4 N/A P = 0.2928
Cortical stroke N = 6 N = 11 N/A P = 0.0366*
Stroke on right hemisphere N = 9 N = 11 N/A P = 0.2844
Stroke on paretic side N = 0 N = 0 N/A P = 1.0000
Stroke on dominant side N = 10 N = 12 N/A P = 0.2654
Systolic BP mmHg 126.7 ± 9.9 126.4 ± 13.4 0.0276 P = 0.9356
Diastolic BP mmHg 79.5 ± 7.0 77.8 ± 10.8 0.1876 P = 0.5840
WMH volume ml 2.6 ± 3.2 3.6 ± 4.2 −0.2910 P = 0.4115
Stroke lesion volume ml 13.8 ± 20.4 20.7 ± 21.2 −0.3339 P = 0.3469
Cortical grey matter volume ml 434.2 ± 45.0 407.1 ± 50.2 0.5716 P = 0.1121
Cerebral white matter volume ml 426.8 ± 54.5 403.2 ± 74.0 0.3697 P = 0.2984
Supratentorial cerebrospinal fluid volume ml 287.5 ± 46.7 294.7 ± 33.0 −0.1758 P = 0.6185
CST MD affected sideb 0.0010 ± 0.0001 0.0011 ± 0.0001 −0.4359 P = 0.2280
CST MD unaffected side 0.0009 ± 0.0001 0.0010 ± 0.0001 −0.1584 P = 0.6580
CST MD ratioc 1.09 ± 0.08 1.13 ± 0.07 −0.4919 P = 0.1752
CST FA affected sideb 0.29 ± 0.03 0.27 ± 0.03 0.6798 P = 0.0645
CST FA unaffected side 0.32 ± 0.03 0.31 ± 0.02 0.4554 P = 0.2084
CST FA ratioc 0.89 ± 0.06 0.86 ± 0.06 0.5346 P = 0.1418
FMA-UE score 41.5 ± 9.5 35.1 ± 10.4 0.6434 P = 0.0667
Table 1. Baseline patient characteristics. Note: aP-value is for difference between groups; bmean diffusivity 
(MD) and fractional anisotropy (FA) in the corticospinal tract (CST) on the side of stroke; cMD and FA in the 
corticospinal tract on the side of stroke versus non-affected side; *P < 0.05; BP = blood pressure; N/A = not 
applicable as Fisher’s exact test used for difference in proportions. WMH = white matter hyperintensity; 
FMA-UE = Fugl-Meyer Assessment, upper-extremity.
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Results
patient characteristics. Of the 37 randomised participants, 35 had brain MRI performed and were 
included in this analysis. There were no statistically significant differences in baseline characteristics between 
VNS-treated and control participants, except for cortical stroke incidence, which was higher in VNS participants 
(Table 1). WMH, stroke, and corticospinal tract image analysis results are illustrated in Fig. 1.
change in fugl-Meyer Assessment, Upper-extremity score between groups. VNS-treated par-
ticipants had greater improvement in FMA-UE score at day-1 post therapy (8.63 ± 5.02 points) versus control 
(3.79 ± 5.04 points; t = 2.83, Cohen’s d = 0.96, P = 0.008). Baseline adjusted regression analysis also showed that 
improvement was greater in VNS participants (Beta = 4.98 points, standard error = 1.74, P = 0.0043).
predictors of follow-up fMA-Ue score in control and VnS groups. Predictors of follow-up FMA-UE 
score in control and VNS groups are shown in Table 2. Baseline FMA-UE score was the strongest predictor of 
six-week follow-up FMA-UE score in both groups: higher baseline scores were associated with higher follow-up 
scores. Higher pre-therapy WMH and CSF volumes were associated with less improvement in FMA-UE score in 
the control but not VNS group. Higher normal appearing white matter volume and lower systolic blood pressure 
were associated with greater improvement in FMA-UE score in the VNS but not control group. Adjusted associ-
ations between FMA-UE score and brain imaging predictors are illustrated in Fig. 2.
The association between WMH volume and FMA-UE score in the control group may have been driven by the 
outlying participant shown in the left panel of the second row in Fig. 2; the association was no longer statistically 
significant after removing this participant.
VnS and control responders. There were 12/16 (75.00%) responders (increase of ≥6-points in FMA-UE) 
in the VNS group versus 6/19 (31.58%) responders in the control group (Fisher’s exact test P = 0.0176). The 
mean baseline FMA-UE score in VNS responders was 34.75 ± 9.64 points. The mean baseline FMA-UE score 
Figure 1. Illustration of brain MRI measures obtained. (A) Raw FLAIR image. (B) Segmentation of white 
matter hyperintensities (WMH; bright red) and ischaemic stroke infarct volumes (royal blue). (C) Estimate 
of the left (cyan) and right (pink) corticospinal tracts. (D) Interaction between stroke lesion (dull red) and 
corticospinal tract (light blue) in a 3D rendering. Images A and B come from the same patient, C and D are from 
separate patients and all are shown in neurological (“left is left”) convention.
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was 40.83 ± 7.63 points in control responders. The difference in baseline FMA-UE score between VNS and con-
trol responders was 6.08 points (t = 1.34, P = 0.198,). Responders in the VNS group had descriptively higher 
stroke (VNS = 21.12 ± 21.67 ml, control = 8.68 ± 18.40 ml, P = 0.2469), WMH (VNS = 2.94 ± 2.33 ml, con-
trol = 1.67 ± 0.80 ml, P = 0.1112), and CSF (VNS = 289.80 ± 33.59 ml, control = 256.20 ± 38.03 ml, P = 0.0727) 
volumes, and descriptively lower cortical grey matter (VNS = 404.30 ± 52.29 ml, control = 434.40 ± 45.98 ml, 
P = 0.2495) and normal appearing white matter (VNS = 402.10 ± 77.46 ml, control = 424.80 ± 56.59 ml, 
P = 0.5361) volumes at baseline.
Discussion
In this combined study of data from two clinical trials, we found that VNS paired with rehabilitation was asso-
ciated with greater improvement in FMA-UE score compared to rehabilitation alone. In a series of exploratory 
analyses, we found that, in controls, features of worse underlying brain health such as higher WMH volume and 
higher CSF volume were associated with worse outcome but this was not the case in people treated with VNS. 
Baseline FMA-UE score was lower and imaging findings less favourable in people who responded to VNS than 
in people who responded to physiotherapy alone. Although these differences were not statistically significant, 
several measures of brain health were consistently worse in VNS participants. This raises the possibility that VNS 
can provide additional benefit versus rehabilitation alone to people with greater baseline disability and cerebro-
vascular disease. These hypotheses need tested in prospective clinical studies.
We found that increased whole brain WMH and CSF volumes were associated with less improvement in 
FMA-UE score in control participants. This was not apparent in VNS treated participants and negative standard 
beta were several times larger in the control group versus the VNS group. One possible inference from these dif-
ferential effects is that VNS can improve outcomes in people with cerebrovascular disease. VNS activates neurons 
in the basal forebrain and locus coeruleus and the ensuing reorganisation of cortical networks (via the release 
of acetylcholine and norepinephrine) may allow motor signals to bypass areas of white matter damage or tissue 
atrophy5. Consistent with this finding, we found higher normal appearing white matter volume in VNS partici-
pants was associated with higher improvement in FMA-UE. Higher systolic blood pressure was associated with 
less improvement in the VNS group but not the control group. VNS has previously been shown to reduce blood 
pressure20 but the reasons for this finding are unclear. These analyses were hypothesis generating and findings 
require confirmation in larger clinical trials. A phase III trial of VNS paired with upper-limb rehabilitation after 
stroke is underway.
The hypothesis that VNS may improve outcomes in those less likely to respond to conventional treatment, 
e.g., those with greater baseline disability, is supported by the fact that baseline FMA-UE was lower in VNS 
responders versus control responders. Although this difference (6.08 points) was not statistically significant, it is 
approximately equal to a level of clinical importance6,7,14. This likely reflects study power and the small sample size 
in this analysis (12 responders in VNS versus 6 in control). Additionally, VNS responders had descriptively worse 
structural brain health at baseline. Again, these differences were not statistically significant but each individual 
structural brain measure (including stroke, WMH, CSF and normal appearing tissue) was worse at baseline in 
VNS responders.
Our study has limitations principally related to the small sample of participants. Although the overall sample 
size was N = 35, we performed analyses within groups of N = 19 and N = 16. These sample sizes are clearly not 
large enough to draw robust conclusions. Limited sample sizes may produce spurious results or miss potentially 
true effects and that may be the case with the results we have presented. Indeed, the statistically significant associ-
ation between WMH volume and FMA-UE score in the control group was no longer significant after removal of 
Predictor Control VNS
Age Beta = −0.07 ± 0.11 (P = 0.554) Beta = −0.11 ± 0.09 (P = 0.223)
Male sex Beta = −0.07 ± 0.23 (P = 0.757) Beta = −0.23 ± 0.18 (P = 0.198)
Baseline Fugl-Meyer Beta = 0.87 ± 0.11 (P < 0.0001)* Beta = 0.94 ± 0.09 (P < 0.0001)*
Time since stroke Beta = −0.01 ± 0.12 (P = 0.962) Beta = −0.15 ± 0.09 (P = 0.118)
Cortical versus subcortical stroke Beta = −0.14 ± 0.22 (P = 0.543) Beta = −0.15 ± 0.22 (P = 0.488)
Months of rehabilitation pre-randomisation Beta = −0.15 ± 0.15 (P = 0.315) Beta = −0.01 ± 0.13 (P = 0.962)
White matter hyperintensity volume Beta = −0.27 ± 0.10 (P = 0.006)* Beta = −0.04 ± 0.10 (P = 0.690)
Cortical grey matter volume Beta = −0.15 ± 0.11 (P = 0.159) Beta = 0.142 ± 0.08 (P = 0.062)
Cerebral normal appearing white matter volume Beta = −0.09 ± 0.10 (P = 0.389) Beta = 0.165 ± 0.08 (P = 0.036)*
Supratentorial cerebrospinal fluid volume Beta = −0.26 ± 0.11 (P = 0.013)* Beta = 0.12 ± 0.13 (P = 0.373)
MD ratio+ Beta = −0.16 ± 0.10 (P = 0.101) Beta = −0.01 ± 0.11 (P = 0.924)
FA ratio+ Beta = 0.10 ± 0.11 (P = 0.387) Beta = −0.03 ± 0.10 (P = 0.786)
Stroke infarct volume Beta = −0.07 ± 0.12 (P = 0.591) Beta = −0.02 ± 0.11 (P = 0.874)
Systolic blood pressure Beta = 0.03 ± 0.13 (P = 0.826) Beta = −0.20 ± 0.03 (P = 0.033)*
Diastolic blood pressure Beta = −0.18 ± 0.13 (P = 0.169) Beta = 0.02 ± 0.12 (P = 0.851)
Table 2. Predictors of 6-week Fugl-Meyer Assessment, upper-extremity score (response) to control and 
VNS treatment. Note: *P < 0.05; Standard error of beta are shown after ± sign beside beta coefficients; +mean 
diffusivity (MD) and fractional anisotropy (FA) in the corticospinal tract on the side of stroke versus non-
affected side.
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Figure 2. Partial regression plots showing adjusted associations with follow-up Fugl-Meyer Assessment, upper-
extremity score (FMA-UE). Associations shown are between: 1. baseline FMA-UE and follow-up FMA-UE, 
adjusted for age and sex (top panel); 2. baseline white matter hyperintensity (WMH) volume and follow-up 
FMA-UE, adjusted for age, sex, and baseline FMA-UE (second top panel); 3. baseline normal appearing white 
matter volume and follow-up FMA-UE, adjusted for age, sex, and baseline FMA-UE (second bottom panel); 4. 
baseline supratentorial cerebrospinal fluid volume and follow-up FMA-UE, adjusted for age, sex, and baseline 
FMA-UE (bottom panel). Scatter plots are shown within the control (left panel) and vagus nerve stimulation 
(VNS; right panel) groups. Residuals for follow-up FMA-UE scores are calculated from the actual versus 
predicted follow-up FMA-UE scores in each model excluding the regressor shown on the x-axis, e.g., follow-up 
FMA-UE was predicted from age, sex, and baseline FMA-UE score in the second top, second bottom, and 
bottom panels. Residuals for brain imaging and baseline FMA-UE score are calculated from actual values minus 
predictions from remaining regressors in each model, e.g., for baseline WMH volume the residuals are actual 
WMH volume minus WMH volume predicted by age, sex, and baseline FMA-UE.
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an outlying participant. Replication of this analysis in a larger sample is required to determine whether this asso-
ciation was no longer statistically significant due to decreased power or the outlying participant. Additionally, the 
developmental, rather than confirmatory, nature of this study meant we performed many statistical tests without 
multiple comparisons testing. Furthermore, it was difficult to determine whether variables were distributed sta-
tistically normal due to the limited number of participants. This further emphasises the need for caution in inter-
preting the results obtained. The VNS group had a larger proportion of participants with cortical stroke than the 
control group. Given we postulate that paired VNS causes task specific plasticity, the effect may differ in different 
stroke subtypes and between group differences could confound results. We have not seen a difference in response 
dependent solely on stroke subtype but the sample size to date does not allow this to be properly assessed. More 
work in a larger sample is required to determine whether cortical versus sub-cortical stroke participants are more 
likely to respond to VNS.
This study was not a hypothesis testing exercise, but an exploratory study designed to formulate hypotheses 
and present the totality of the only currently available data on VNS treatment for upper-limb weakness after 
stroke. These findings now need assessed in a large clinical trial.
While acknowledging the aforementioned limitations, our exploratory analyses have formed the hypotheses 
that VNS may provide additional benefit to patients with more severe baseline upper-limb disability and unfa-
vourable imaging findings, such as higher CSF volume, that reduce the likelihood of success from therapy alone. 
A phase III trial that is currently underway will formally assess these hypotheses and the efficacy of VNS paired 
with rehabilitation for arm weakness after ischemic stroke.
Data availability
Data used in this analysis will remain confidential until one year after the commercial sponsor, MicroTransponder, 
Inc., obtains FDA approval or until regulatory approval has been abandoned.
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